Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up

American Journal of Hematology
Federico MosnaMichele Gottardi

Abstract

Approximately 40% of patients affected by core binding factor (CBF) acute myeloid leukemia (AML) ultimately die from the disease. Few prognostic markers have been identified. We reviewed 192 patients with CBF AML, treated with curative intent (age, 15-79 years) in 11 Italian institutions. Overall, 10-year overall survival (OS), disease-free survival (DFS), and event-free survival were 63.9%, 54.8%, and 49.9%, respectively; patients with the t(8;21) and inv(16) chromosomal rearrangements exhibited significant differences at diagnosis. Despite similar high complete remission (CR) rate, patients with inv(16) experienced superior DFS and a high chance of achieving a second CR, often leading to prolonged OS also after relapse. We found that a complex karyotype (i.e., ≥4 cytogenetic anomalies) affected survival, even if only in univariate analysis; the KIT D816 mutation predicted worse prognosis, but only in patients with the t(8;21) rearrangement, whereas FLT3 mutations had no prognostic impact. We then observed increasingly better survival with more intense first-line therapy, in some high-risk patients including autologous or allogeneic hematopoietic stem cell transplantation. In multivariate analysis, age, severe thrombocytopenia...Continue Reading

References

Jan 5, 2001·British Journal of Cancer·C D DalleyA Z Rohatiner
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K MrózekC D Bloomfield
Mar 22, 2003·Blood·Jacques DelaunayUNKNOWN Bordeaux-Grenoble-Marseille-Toulouse cooperative groups
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John C ByrdClara D Bloomfield
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Nov 11, 2005·Leukemia·G PereaUNKNOWN Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Apr 7, 2006·Leukemia·N BoisselUNKNOWN Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaUNKNOWN Cancer and Leukemia Group B
Aug 31, 2006·British Journal of Haematology·Frederick R AppelbaumElihu H Estey
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Aug 12, 2008·Seminars in Oncology·Peter Paschka
Oct 23, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hideki NakasoneKensuke Usuki
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas PrébetUNKNOWN Core Binding Factor Acute Myeloid Leukemia (CBF AML) intergroup
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea CorbaciogluKonstanze Döhner
Mar 12, 2011·Journal of the National Comprehensive Cancer Network : JNCCN·Margaret R O'DonnellUNKNOWN National Comprehensive Cancer Network
Apr 2, 2011·Cancer·Cathy J BradleyGordon D Ginder
Dec 26, 2012·Clinical Lymphoma, Myeloma & Leukemia·Vijaya Raj BhattGautam Borthakur
Jul 3, 2013·Cytogenetic and Genome Research·A SimonsR J Hastings
Aug 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettDonald Milligan
Dec 10, 2013·Hematology·Peter Paschka, Konstanze Döhner

❮ Previous
Next ❯

Citations

Feb 18, 2016·Stem Cells International·Federico Mosna, Michele Gottardi
Jun 28, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John P LeonardGail J Roboz
Feb 14, 2019·Annals of Hematology·Ho-Jin ShinUNKNOWN Korean Society of Hematology AML/MDS Working Party
Jul 30, 2019·European Journal of Haematology·Yu-Chiao ChiuChieh-Lin Jerry Teng
Apr 21, 2020·Expert Review of Hematology·Xavier ThomasMaël Heiblig
Jan 31, 2016·Current Opinion in Hematology·Laura E Finn, James M Foran
Jun 8, 2017·Journal of Clinical Medicine·Federico MosnaMichele Gottardi
Sep 4, 2016·Journal of Hematology & Oncology·Francesco SaraceniUNKNOWN Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)
Sep 22, 2020·Minerva medica·MIchele GottardiClaudio Cerchione
Sep 15, 2020·International Journal of Laboratory Hematology·Celalettin UstunGuido Marcucci
Jul 30, 2021·Haematologica·Shannon R McCurdy, Selina M Luger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.